ARVN - Arvinas gains on protein degrader data

Arvinas (ARVN) soars 97% in premarket after it says interim Phase 1 data for ARV-471 show evidence of anti-tumor activity and robust efficacy signals in heavily pretreated patients with locally advanced or metastatic ER positive / HER2 negative breast cancer.Data showed one confirmed partial response ((PR)), two additional patients with unconfirmed PRs, and a clinical benefit rate of 42%.Phase 1B combination trial of ARV-471 and Ibrance expected to commence this month; Phase 2 expansion cohort for ARV-471 seen to begin 1H 2021.Company says ARV-110 continues to demonstrate a favorable safety profile, tolerability and anti-tumor activity in a heavily pretreated prostate cancer patient population. Showed prostate specific antigen reduction (>50%) of 40%.

For further details see:

Arvinas gains on protein degrader data